AFFiRiS reports encouraging outcomes from clinical studies of the two Alzheimer’s vaccines AFFiRiS AG today announced that the primary endpoints have been met for the Stage I clinical studies of its two Alzheimer’s vaccines AD01 and AD02, which demonstrated favourable security and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals buy drugs online . All 48 sufferers treated in these research were given four vaccinations that have been well tolerated and no serious side results associated with the vaccine applicants were observed. The results demonstrate the potential value of the AFFITOME technology, which forms the platform for both of these vaccines and could create a generation of extremely specific vaccines.
Tumor-bearing mice treated with CoFactor, 5-FU and capecitabine had the greatest inhibition of tumor development compared to the other drug regimens tested in this study, including capecitabine alone and a matched treatment program of leucovorin , 5-FU, and capecitabine. The mean tumor level of the CoFactor, 5-FU and capecitabine-treated mice was statistically significantly less than mice treated with either capecitabine alone or mice treated with LV, 5-FU and capecitabine . Consistent with superior inhibition of tumor growth, treatment with CoFactor, 5-FU and capecitabine also prolonged survival compared to the other treatment regimens.